UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Lonza Group AG
of Switzerland
(2018
sales of 5.54 billion Swiss Francs [US$5.61 billion]
of which 56%
was Pharma&Biotech),
Protek PAO
of Russia
(251.73 billion Russian Rubles [US$3.96 billion]
of which 72%
was Distribution), and
Grifols SA
which is
based in Spain
(4.49 billion Euro [US$4.96 billion]
of which 78%
was Bioscience).
Sales Analysis.
UCB Sa reported sales of 4.63 billion Euro (US$5.12 billion)
for the
year ending
December of 2018.
This
represents
an
increase of 2.3%
versus 2017, when the company's sales were 4.53 billion Euro.
This was the fourth straight year of sales growth at UCB Sa.